|
 |
| home > ebr > spring 2003 > biotech companies in the pharma market - grow or be doomed, warns dr volker janssen, director at simon-kucher & partners |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review
|
| The German biotech industry is booming. According to a study carried out by management consultancy Ernst & Young, the number of biotech companies with less than 500 employees (this accounts for the majority of German biotechs) increased by more than 90 per cent between 1997 and 2000, which means there are now more than 300 biotech companies operating in Germany. The turnover generated by these companies has nearly tripled, as has the number of employees. In 2000, the Biotech Index on the Neuer Markt in Frankfurt was often quoted at 50 per cent above the NEMAX Allshare Index. In view of Germany's unparalleled growth in the biotech arena one was inclined to believe Deutsche Bank's forecasts for the sector: a turnover increase for SME |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Dr Volker Janssen, Director at Simon-Kucher & Partners
Dr Volker Janssen is a Director in the Life Science division of Simon-Kucher & Partners Strategy & Marketing Consultants. He specialises in consulting to pharmaceutical clients, mainly in the areas of strategic marketing, corporate communications, sales force management, market segmentation, international pricing and value-to-customer.
He has worked for a number of companies in Europe, Japan and the US, including Aventis, Pfizer, Novo Nordisk, Fujisawa, Johnson & Johnson, Eli Lilly, 3M, Sanitec and DHL. Dr Janssen is the author of numerous publications on pricing, sales force management and communication and has spoken frequently at conferences and seminars on these subjects.
|
|
|
|
|
|
 |
Industry Events |
 |
Line Clearance in Pharmaceutical Packaging & Manufacturing
5 February 2009, Manchester, UK
More info >>
|
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
